Pipeline
Curatis identifies potential drug candidates in indications with high unmet medical need via its extensive network within the scientific and medical community.
Our strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization. All of Curatis' development projects have been selected in line with this strategy.
Peritumoral Brain Edema
Active compound: corticorelin
Next major development step: pivotal clinical study. Targeting the treatment of brain swelling caused by tumors.
Severe Migraine with Aura Prevention
Addressing a high unmet medical need in patients suffering from severe migraine with aura.
Medication Overuse Headache
A novel treatment approach for patients suffering from medication overuse headache.
Fibrotic or Inflammatory Orphan Diseases
Targeting a range of rare fibrotic and inflammatory conditions with significant unmet medical need.
Partnerships for Developing Novel Medicines
To ensure efficient and state-of-the-art developments of its pipeline projects, Curatis maintains co-development partnerships with other innovative small and medium-sized biotech/pharmaceutical companies, and also with best-practice contract research and manufacturing organisations.
Curatis is looking for larger pharmaceutical companies for licensing or co-development arrangements for the late-stage clinical development of its pipeline projects.